finance.yahoo.com ·
Alumis Stock Over 300 One
Topic context
This topic has been covered 381566 times in the last 30 days across our monitored publishers.
The full article is on the original publisher site. This page only shows the headline and a very short excerpt.
AI insight
AI-generatedThe article reports an insider sale by Omega Fund Management in Alumis, a biotech firm developing autoimmune disease therapies. The commercial mechanism is weak: the sale is a portfolio rebalancing event, not a fundamental change in Alumis's business. The company's upcoming FDA submission is a key catalyst but no concrete outcome or timeline is provided. The impact is single-company-specific with no broader sector or supply chain implications.
Signals our AI researcher identified
Extracted by our AI model from this article and related public sources — not direct quotes from the publisher.
- Omega Fund Management sold 411,968 shares of Alumis (NASDAQ:ALMS) for ~$10.3 million on May 15, 2026.
- Alumis shares priced at $22.87, reflecting a 327% increase over the past year.
- Alumis has a market cap of $2.9 billion, revenue of $24.05 million, and net loss of $243.33 million.
- Alumis plans to submit data for FDA approval in Q4 2026.
- Insider sale reduced Omega's stake to 241,255 shares, decreasing position value by $1.06 million from prior quarter.
Related stories
fool.com
Keysight Keys Q2 2026 Earnings Transcript
livemint.com
Haryana Bars Petrol Diesel Cabs for Aggregators What Means Pm Modis Austerity Push Ncrs Aqi Fuel News
economictimes.indiatimes.com
The Rs 3 Relief That Wasnt Why Investors Are Dumping Oil Stocks After Long Awaited Petrol Diesel Price Hike
proactiveinvestors.com.au
The Morning Catch Up Asx Set to Open Lower Ahead of Pivotal Nvidia Earnings
nbclosangeles.com